In the following subsections, we will focus on the most relevant studies regarding relaxin-2 circulatory levels in different backgrounds of CVDs, especially in HF, AF, ischemic heart disease, MI, aortic valve disease, hypertension, and atherosclerosis. This evidence concerns the gene RLN2 and atrial fibrillation.